|
|
Volumn 96, Issue 4, 2004, Pages 252-253
|
|
Aspirin for cancer chemoprevention: Still a headache?
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ACETYLSALICYLIC ACID;
CYCLOOXYGENASE 1;
CYCLOOXYGENASE 2;
IMMUNOGLOBULIN ENHANCER BINDING PROTEIN;
LIPOXYGENASE;
NONSTEROID ANTIINFLAMMATORY AGENT;
PROSTAGLANDIN;
TRANSCRIPTION FACTOR;
ANGIOGENESIS;
ANTINEOPLASTIC ACTIVITY;
APOPTOSIS;
BARRETT ESOPHAGUS;
CANCER PREVENTION;
CANCER RISK;
CARCINOGENESIS;
CELL PROLIFERATION;
CELL TRANSFORMATION;
CHEMOPROPHYLAXIS;
COLORECTAL CANCER;
CORONARY ARTERY DISEASE;
COST EFFECTIVENESS ANALYSIS;
DOSE RESPONSE;
DRUG MECHANISM;
DRUG TARGETING;
ENZYME INHIBITION;
ESOPHAGUS CANCER;
EVIDENCE BASED MEDICINE;
GASTROINTESTINAL HEMORRHAGE;
GENE ACTIVITY;
GENE TARGETING;
HEALTH CARE COST;
HODGKIN DISEASE;
HUMAN;
IMMUNE DEFICIENCY;
IMMUNE RESPONSE;
IMMUNOMODULATION;
LOW DRUG DOSE;
LYMPHOCYTE;
NONHODGKIN LYMPHOMA;
NOTE;
PANCREAS CANCER;
PRIORITY JOURNAL;
PROSTAGLANDIN SYNTHESIS;
QUALITY ADJUSTED LIFE YEAR;
REED STERNBERG CELL;
RISK BENEFIT ANALYSIS;
RISK REDUCTION;
STROKE;
TUMOR CELL LINE;
|
|
EID: 1342312281
PISSN: 00278874
EISSN: None
Source Type: Journal
DOI: 10.1093/jnci/96.4.252 Document Type: Note |
|
Times cited : (14)
|
|
References (0)
|